LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the LeMaitre Vascular Q4 2025 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Thank you. Good afternoon, and thank you for joining us on our Q4 2025 Conference Call. With me on today's call is our CEO, George LeMaitre, and our president, Dave Roberts. Before we begin, I'll read our safe harbor statement. Today, we'll be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, February 25, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we may discuss non-GAAP financial measures. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and will be available in the investor relations section of our website, www.limate.com. I'll now turn the call over to George Limate. Thanks, Dorian. Q4 featured 16% sales growth, a 71.7% gross margin, and 47% off-income growth. Q4 sales were led by graph, up 27%, Valvetomes up 20%, and Schuntz ...